Next-Generation Sequencing-Based Genomic Profiling of Children with Acute Myeloid Leukemia

Area of Science:

• Oncology
• Genetics
• Pediatrics

Background:

• Pediatric acute myeloid leukemia (AML) is a significant cause of childhood cancer mortality.
• Limited research exists on the molecular characteristics of pediatric AML.
• Understanding the genetic landscape is crucial for improving treatment outcomes.

Purpose of the Study:

• To perform an integrative analysis of cytogenetic and molecular profiles in a cohort of pediatric AML patients.
• To identify recurrently mutated genes and compare findings with previous studies.
• To investigate the association of specific mutations with treatment response and disease progression.

Main Methods:

• Targeted next-generation sequencing of 54 genes in 75 pediatric AML patients.
• Analysis of a multicentric, real-world patient cohort treated per Berlin-Frankfurt-Münster protocols.
• Comparison of mutational profiles at diagnosis and relapse.

Main Results:

• Seventeen genes were recurrently mutated in over 5% of patients.
• Identified higher frequencies of BCORL1, CUX1, KDM6A, PHF6, and STAG2 mutations than previously reported.
• Discovered novel BCORL1 mutations in 9% of patients and found tumor suppressor gene mutations (PHF6, TP53, WT1) associated with induction failure and shorter event-free survival.
• Observed an enrichment of mutations in tumor suppressor genes and transcription factors at relapse compared to diagnosis.

Conclusions:

• The molecular landscape of pediatric AML shows considerable heterogeneity and differs from previous findings.
• Specific mutations, particularly in tumor suppressor genes, are linked to poor treatment outcomes and disease progression.
• Relapse in pediatric AML is characterized by an increased burden of mutations in tumor suppressor genes and transcription factors.
• These findings contribute to a better molecular understanding and risk stratification for pediatric AML.